Company
United Therap
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
6
5 still marketed
Novel approvals
2
Approvals since 2021
2
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Tyvaso Dpi approved Priority reviewOrphanMay 23, 2022
- Tyvaso new use OrphanMar 31, 2021
- Orenitram new use OrphanOct 18, 2019
- Remodulin approved OrphanJul 30, 2018
- Tyvaso new use OrphanOct 19, 2017
- Orenitram new use OrphanJan 28, 2016
- Unituxin approved NovelPriority reviewOrphanMar 10, 2015
- Tyvaso new use OrphanMay 20, 2014
- Orenitram approved OrphanDec 20, 2013
- Tyvaso approved OrphanJul 30, 2009
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (5)
Newest FDA action first.
- Tyvaso Dpi Treprostinil · 2022
- Orenitram Treprostinil Diolamine · 2013
- Tyvaso Treprostinil · 2009
- Unituxin Dinutuximab · 2015
- Remodulin Treprostinil · 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.